|
Price: $20.5000
$-0.05 
-0.243%
|
| Day's High:
| $20.78
| Week Perf:
| 1.69 %
|
| Day's Low: |
$ 20.20 |
30 Day Perf: |
-9.81 % |
| Volume (M): |
369 |
52 Wk High: |
$ 38.20 |
| Volume (M$): |
$ 7,567 |
52 Wk Avg: |
$27.20 |
| Open: |
$20.57 |
52 Wk Low: |
$20.01 |
|
|
| Market Capitalization (Millions $) |
1,226 |
| Shares
Outstanding (Millions) |
60 |
| Employees |
201 |
| Revenues (TTM) (Millions $) |
113 |
| Net Income (TTM) (Millions $) |
-128 |
| Cash Flow (TTM) (Millions $) |
-15 |
| Capital Exp. (TTM) (Millions $) |
42 |
Xencor Inc
Xencor Inc is a biopharmaceutical company that uses its proprietary XmAb technology platform to develop and commercialize novel antibody therapeutics. The company's mission is to improve patient outcomes and quality of life by developing innovative and differentiated therapeutics.
Xencor's XmAb technology platform is a versatile antibody engineering technology that enhances the efficacy and safety of antibodies. It can be used to improve the half-life of antibodies, increase their potency, and reduce their immunogenicity. The XmAb technology platform has been applied to the development of several antibody candidates in various therapeutic areas including oncology, autoimmune diseases, and allergic diseases.
One of the key strengths of Xencor is its collaboration strategy. The company has partnered with several pharmaceutical and biotechnology companies including Novartis, Alexion Pharmaceuticals, and MorphoSys to develop and commercialize XmAb-based therapeutics. Xencor has also entered into research collaborations with academic institutions and government agencies.
Xencor has a diverse pipeline with several candidates in different stages of clinical development. The company's lead candidate, XmAb5871, is a first-in-class monoclonal antibody that targets the Fc'RIIb receptor on B cells. It is being developed for the treatment of autoimmune diseases including systemic lupus erythematosus and IgG4-related disease. XmAb7195 is another candidate being developed in collaboration with Novartis for the treatment of acute myeloid leukemia and other hematologic malignancies.
In addition to its pipeline of candidates, Xencor also has a robust technology portfolio. The company has developed several proprietary technologies including Xtend' Fc technology, which extends the half-life of antibodies, and bispecific Fc technology that enables the creation of bispecific antibodies with improved therapeutic properties.
Overall, Xencor is a leading biopharmaceutical company with a promising pipeline of candidates and innovative technology platform. The company's collaborations, proprietary technologies, and diverse pipeline positions it to continue to deliver value to patients and shareholders in the years to come.
Company Address: 465 North Halstead Street, Suite 200 Pasadena 91107 CA
Company Phone Number: 305-5900 Stock Exchange / Ticker: NASDAQ XNCR
| XNCR is expected to report next financial results on November 06, 2023. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Immuron Limited
In the financial fourth quarter of 2023, Immuron Limited, a major pharmaceutical preparations company, reported its financial results, which revealed a decrease in revenue and widened net loss. These figures mark a notable change compared to the corresponding financial reporting period from the previous year. This article aims to examine the context behind Immuron Limited's financial results, including its stock performance and implications for investors.
Financial Results:
Immuron Limited disclosed a revenue of $1.480365 million in the financial fourth quarter of 2023 after experiencing a net loss of $-3.787 million. These figures signify a departure from balanced books in the corresponding period a year earlier. Additionally, in the financial year 2023, the company announced a loss of $-3.79 million alongside a revenue of $1.48 million. In comparison to the prior financial year, the net loss per share has widened from $-1.25 to $-1.66, indicating a financial decline. However, it is important to note that the net loss remained unchanged from $0.00 million a year earlier.
|
|
Procyon Corporation
Procyon Corporation recently released their financial results for the fourth quarter of the 2023 earnings season. While the company reported unaltered earnings per share (EPS), a decline in revenue and other key indicators raises concerns about the company's future performance. This article aims to interpret the financial results and discuss their potential impact on Procyon Corporation going forward.
1. Earnings per Share (EPS) and Revenue Performance:
Procyon Corporation maintained an EPS of $0.00 in the fourth quarter, suggesting stability in their profitability. However, the company experienced a modest revenue decline of -0.589% year-on-year, amounting to $1.20 million. This decline sets Procyon apart from the rest of the Major Pharmaceutical Preparations industry, which recorded a revenue improvement during the same period.
|
|
Innovation Pharmaceuticals Inc
Innovation Pharmaceuticals Inc, a pharmaceutical company, recently announced its financial results for the fiscal year ending June 30, 2023. During this period, the company achieved a break-even point of $0.00 per share, which was the same as the previous year and the previous quarter.
However, the company did not generate any revenue during this quarter, remaining at $0.00 million, the same as the previous year and quarter. This indicates that there was no growth in the company's revenue during this period.
Additionally, Innovation Pharmaceuticals Inc reported a net shortfall of $-0.681 million for the fiscal year ending June 30, 2023. This is a significant improvement compared to the deficit of $-1.626 million reported in the same quarter a year ago. Although still in a shortfall, the company has managed to reduce its losses, which may indicate positive efforts in managing their expenses.
|
|
Palatin Technologies Inc
Financial News Report:
Palatin Technologies Inc Reports Strong Revenue Growth in Q4 2023, Despite Stock Deficit
Palatin Technologies Inc (PTN) has announced a substantial revenue advancement of 109.038% year on year to $1.76 million in the fourth quarter of 2023. However, the company posted a deficit per stock at $-0.98. Despite the stock deficit, PTN's revenue experienced significant growth compared to its peers in the Major Pharmaceutical Preparations industry. Most corporations in this industry saw an average revenue advance of 3.04% during the same period.
In comparison to the preceding reporting period, PTN's revenue surged by 47.359% from $1.20 million and the deficit improved from $0.00 per share. This strong revenue growth indicates a positive trend for Palatin Technologies Inc.
|
|
Ibio Inc
In the aftermath of Ibio Inc's recently released fourth-quarter earnings report, the company appears to be grappling with mounting losses and a steep decline in its share value. The financial results for the quarter ended in 2023 revealed a concerning trend of escalating losses for the biotechnology firm.
Earnings Overview:
During the fourth quarter of the 2023 earnings season, Ibio Inc reported a significant increase in its loss per share compared to the same period in the prior year. The loss per share surged from $-0.10 a year ago to $-0.97, representing a substantial deterioration. Additionally, the company witnessed a sequential increase in losses, reaching $-0.55 per share from the previous financial reporting period.
|
| Per Share |
Current |
| Earnings (TTM) |
-2.14 $ |
| Revenues (TTM) |
1.9 $
|
| Cash Flow (TTM) |
- |
| Cash |
0.58 $
|
| Book Value |
11.35 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-2.14 $
|
| Revenues (TTM) |
1.9 $ |
| Cash Flow (TTM) |
- |
| Cash |
0.58 $
|
| Book Value |
11.35 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
